Assocation of endostatin D104N with leukemia

Area of Science:

• Genetics
• Oncology
• Molecular Biology

Background:

• Endostatin is a key angiogenesis inhibitor.
• Genetic variations in endostatin may influence cancer development.
• Leukemia encompasses various blood cancers.

Purpose of the Study:

• To investigate the association between endostatin polymorphisms (D104N, nucleotide 4349G --> A) and the risk of leukemia.
• To compare the frequencies of these polymorphisms in leukemia patients and healthy controls.

Main Methods:

• Polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) assay was used.
• Bone marrow and peripheral blood samples from 126 acute myeloid leukemia (AML), 57 chronic myeloid leukemia (CML), 91 acute lymphocytic leukemia (ALL) patients, and 178 normal controls were analyzed.
• Allele and genotype frequencies of the endostatin D104N polymorphism were determined.

Main Results:

• The allele frequencies of 4349G and 4349A in normal Taiwanese controls were 98% and 2%, respectively.
• Homozygous 4349G (104D/D) and heterozygous 4349G/A (104D/N) genotypes were observed in 95.5% and 4.5% of controls, respectively.
• Similar frequencies of endostatin polymorphisms were found in leukemia patients (AML, CML, ALL) and normal controls, with no homozygous 4349A (104N/N) individuals identified in either group.

Conclusions:

• The endostatin D104N polymorphism (nucleotide 4349G --> A) does not appear to be associated with the risk of developing leukemia.
• Further research may be needed to explore other genetic factors influencing leukemia susceptibility.